



POLYCAT UK

Nanomaterials and photonic solutions. Novel ‘at source’ approaches to stop hospital derived pharmaceuticals reaching the sewer network

Manuel-Thomas Valdivia

Supervisory Team: Prof Ian Megson, Prof Alistair Kean, Dr Mark Taggart, Dr Szabolcs Pap




Background

630 different pharmaceuticals and their transformation products have been detected in 71 countries worldwide

Global drug prescribing volumes are increasing continuously

Number of pharmaceuticals detected in surface water, groundwater, tap water, and/or drinking water



Still many drug compounds are not classified or routinely monitored in surface or drinking water !

Active pharmaceutical ingredients (APIs) have shown detrimental toxic effects on aquatic organisms ...

- Birth control pill -> Feminisation of male fish
- Analgesics, antidepressants -> Fish migration

...and may accumulate in food chains:

Diclofenac poisoning in vulture populations



Background


- Hospitals are a point source for ecotoxic drugs and metabolites in our environment
- Drug concentration in wastewater: ng/L – ug/L
- Conventional biological wastewater treatment eliminates APIs poorly
- Persistent, lipophilic APIs reach our water bodies, pose ecotoxic risks and may accumulate in food chains

Novel at-source wastewater treatment concepts are urgently needed to eliminate a wide range of harmful organic drug compounds !




Overview photocatalysis

- Light activated oxidation of organics in the presence of water and a photocatalyst
 - Metal Oxide Semiconductor (MOS)
- Non-selective, holistic approach for drug elimination via generation of ROS species




Treatment concept photocatalysis

- Generation of excited electrons and holes via illumination of semiconductor materials
- ROS production via redox reactions on the electrolyte interface of the photocatalyst
- Oxidation of organic drug compounds – Transformation of APIs into likely non-toxic compounds




Current limitations of photocatalysis

- **Recombination of charge-separated electron-hole pairs in wide band gap (≥ 3.1 eV) photocatalysts**
- Electrons do not reach the MOS-surface
- Conduction band electrons simply return to holes in the valence band




Current limitations of photocatalysis


- **Low photocatalytic activity under visible light in wide band-gap (≥ 3.1 eV) photocatalysts**
- Recombination of charge-separated electron-hole pairs




TiO₂ Solar Disinfection
min. 6 hours light exposure



UV-A 300 – 400 nm
VIS 400 – 700 nm

Solar irradiance: 
UV-A 4-6% VIS 43%



TiO₂ photocatalysts only absorb a small fraction of the UV-VIS spectrum !

Novel photocatalytic materials

Conventional MOS:

TiO₂ 3.2 eV

- + non-toxic, stable, cheap
very good UV-light performance
- Poor VIS-light performance

Novel photocatalysts:

g-C₃N₄ (graphitic carbon nitride) 2.7 eV

- + non-toxic, no metal leaching,
thin-film layers enhance VIS-light performance
- unmodified - limited VIS-light performance

B₂O₃, BiVO₄, Bi₂WO₆ (bismuth-based) 2.3 – 2.6 eV



- + non-toxic, enhanced VIS-light performance

ZnO (zinc oxide) 3.37 eV

- + good surface modification properties
excellent UV-light performance
- Poor VIS-light performance

Surface tuning to enhance UV-VIS activity

- Combination of different band gap materials for better performance
- Example: Noble metal doping




Project Plan

Aim of this project: Demonstrate proof-of-principle that photocatalytic approaches can eliminate (oxidise) persistent pharmaceuticals

- 1 Literature review
- 2 Compound selection
- 3 Develop analytical techniques - HPLC-MS vs Raman spectroscopy to identify pharmaceuticals at low ng/L concentrations
- 4 Develop experimental set-up:
Drug dilutions in tap-water with conventional photocatalysts such as powdered TiO₂ (varying light, oxygen input and drug exposure time)
- 5 Conduct immobilisation experiments of photocatalysts on surfaces (physical deposition)
- 6 Test novel photocatalytic materials (Bi₂O₃, BiVO₄, g-C₃N₄) for better performance
- 7 Modify metal oxide surfaces for enhanced photocatalytic activity

Ecotoxicity of different drugs



$$RQ = \frac{MEC_{max}}{PNEC}$$

MECmax =
Maximal drug concentration measured in hospital effluents

PNEC =
Predicted no-effect concentration (concentration below which no toxic effects in daphnia, fish, algae are observed)

Compound selection criteria

1. Ecotoxicity
2. Persistence in the environment (physico-chemical characteristics)
3. Prescribing volumes

Development of experimental set-up for drug decay analysis

Drug dilutions in tap-water at pH 7 + UV-light + photocatalyst Further experiments with prototype filter set-up

Commercial powdered P25 TiO₂ in a stirred beaker suspension

- Highest possible photocatalytic activity
→ use of maximal nanoparticle surface area
- Difficult photocatalyst recovery !



POLYCAT UK

Immobilisation of P25 TiO₂ on different supports

- Glass beads: Dip-coating (sol-gel)
- Textile: Heat deposition
- Flat surfaces, diverse materials:
Physical Vapour Deposition (PVD)

Beyond proof-of-principle:

- Toxicity studies on photocatalytic transformation products
- Surface tuning of photocatalysts

Thank you